CompletedPhase 1

A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)

United States18 participantsStarted 2024-03-19

Plain-language summary

This study examined the safety of the drug MK-6552 and if people tolerated it. It also studied whether MK-6552 works better than placebo for staying awake in sleep deprived healthy participants.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Criteria include but are not limited to the following: * Is in good health * Body Mass Index (BMI) between 18 and 32 kg/m\^2, inclusive. Exclusion Criteria: Criteria include but are not limited to the following: * History of or current hypertension, * Has a history of sleep disorders:

What they're measuring

Participants with an Adverse Event (AE)

Timeframe: Up to Day 30

Participants who discontinued from study due to an AE

Timeframe: Day 1

Maintenance of Wakefulness Test (MWT) for MK-6552

Timeframe: Postdose time to maximum plasma concentration (Tmax) (at designated timepoints up to 24 hours postdose)

Trial details

NCT IDNCT06619665

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-07-16

View on ClinicalTrials.gov More Healthy trials